Covid19
DiaSorin Q1 Revenues Rise 34 Percent Despite Dip in COVID-19 Test Demand | Genomeweb
The firm saw strong year-over-year diagnostic test growth despite a 5 percent drop in COVID-19 serology and molecular test revenues.
The firm saw strong year-over-year diagnostic test growth despite a 5 percent drop in COVID-19 serology and molecular test revenues.
